Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has granted 11,847 restricted stock units (RSUs) to a new employee. The RSUs will vest in four equal annual installments over four years, contingent upon continued employment. The grant was made under the Company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Solid Biosciences (Nasdaq: SLDB), un'azienda nel settore delle scienze della vita che si concentra sullo sviluppo di farmaci genetici di precisione per le malattie neuromuscolari e cardiache, ha concesso 11.847 unit脿 azionarie vincolate (RSU) a un nuovo dipendente. Le RSU verranno assegnate in quattro rate annuali uguali nell'arco di quattro anni, condizionatamente all'impiego continuato. La concessione 猫 avvenuta nell'ambito del Piano di Incentivazione Azionaria 2024 dell'azienda e rispetta la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'impiego.
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en el desarrollo de medicamentos gen茅ticos de precisi贸n para enfermedades neuromusculares y card铆acas, ha otorgado 11,847 unidades de acciones restringidas (RSUs) a un nuevo empleado. Las RSUs se conceder谩n en cuatro partes anuales iguales durante cuatro a帽os, condicionadas a la continuaci贸n del empleo. La concesi贸n se realiz贸 bajo el Plan de Incentivos de Acciones 2024 de la empresa y cumple con la Regla de Cotizaci贸n de Nasdaq 5635(c)(4) como un incentivo de empleo.
靻旊Μ霌� 氚旍澊鞓れ偓鞚挫柛鞀� (Nasdaq: SLDB)電� 鞁犼步攴� 氚� 鞁灔 歆堩櫂鞚� 鞙勴暅 鞝曤皜 鞙犾爠 鞚橅暀 臧滊皽鞐� 歆戩頃橂姅 靸濍獏 瓿柬暀 須岇偓搿�, 靸堧鞖� 歆侅洂鞐愱矊 11,847臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅鞀惦媹雼�. RSU電� 瓿犾毄鞚� 歆�靻嶋悩電� 臁瓣贝鞙茧 4雲� 霃欖晥 鞐瓣皠 4須� 霃欕摫頃橁矊 歆�旮夒惄雼堧嫟. 鞚措矆 攵�鞐姅 須岇偓鞚� 2024雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞙茧┌, Nasdaq 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 瓿犾毄 鞙犾澑鞚� 欷�靾橅暕雼堧嫟.
Solid Biosciences (Nasdaq: SLDB), une entreprise de sciences de la vie sp茅cialis茅e dans le d茅veloppement de m茅dicaments g茅n茅tiques de pr茅cision pour les maladies neuromusculaires et cardiaques, a accord茅 11.847 unit茅s d'actions restreintes (RSUs) 脿 un nouvel employ茅. Les RSUs seront acquises en quatre versements annuels 茅gaux sur quatre ans, sous r茅serve de l'emploi continu. La concession a 茅t茅 faite dans le cadre du Plan d'Incitation 脿 l'Action 2024 de l'entreprise et est conforme 脿 la R猫gle de Cotation Nasdaq 5635(c)(4) en tant qu'incitation 脿 l'emploi.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen im Bereich der Lebenswissenschaften, das sich auf die Entwicklung pr盲ziser genetischer Medikamente f眉r neuromuskul盲re und kardiovaskul盲re Erkrankungen konzentriert, hat 11.847 restricted stock units (RSUs) an einen neuen Mitarbeiter gew盲hrt. Die RSUs werden in vier gleichen j盲hrlichen Raten 眉ber vier Jahre angerechnet, vorausgesetzt, die Anstellung bleibt bestehen. Die Gew盲hrung erfolgte im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens und entspricht der Nasdaq-Listing-Regel 5635(c)(4) als Besch盲ftigungsanreiz.
- None.
- None.
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.聽(Nasdaq: SLDB) (the 鈥淐ompany鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (鈥淩SUs鈥�) to one newly hired employee.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee鈥檚 continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company鈥檚 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee鈥檚 acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About聽Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid鈥檚 mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
How many RSUs did Solid Biosciences (SLDB) grant in December 2023?
What is the vesting schedule for Solid Biosciences (SLDB) December 2023 RSU grant?
Under which plan did Solid Biosciences (SLDB) issue the December 2023 RSU grant?
